Local vaccine production: a priority for the Eastern Mediterranean Region

The document outlines a regional strategy to strengthen local vaccine production in the Eastern Mediterranean Region. It notes that limited access to affordable vaccines, disruptions during COVID-19, and requests from ministries of health motivated the need for increased local production. Currently, several countries in the region have partial production capabilities. The strategy aims to promote sustainable local vaccine production through establishing strategic plans, facilitating technology transfers, investing in workforce development, strengthening regulatory systems, and implementing critical actions. It seeks regional vaccine security and asks what is needed to finalize and effectively implement the strategy, as well as expectations from WHO support.

Government & Nonprofit

1
Local vaccine production:
a priority for the Eastern
Mediterranean Region
Regional strategy to strengthen
local vaccine production
Dr Houda Langar
Regional Advisor, Access to Medicines and Health Technologies

2
Why does our Region need vaccine production so much?
Limited access to
affordable, quality
new vaccines,
particularly in LMICs
Interest from
manufacturers
Disruptions of
supplies during the
COVID-19 pandemic
MOH requests to
strengthen local
vaccine production

3
Vaccine production status in the Region before
COVID-19
BCG TT DT DTP OPV HepB
DTP-
HepB
DTP-
Hib-
HepB
Measles Rubella
Meningo
coccal A,C
Rotavirus Rabies
Egypt
I.R.of Iran
Pakistan
Tunisia
Saudi Arabia
Full production Fill &Finish Secondary Packaging
Manufactured Suspended
TT = tetanus toxoid
DT = diphtheria, tetanus
DTP = diphtheria, tetanus, pertussis
OPV = oral polio vaccine
HepB = hepatitis B
Hib = Haemophilus influenzae type b
Setback to vaccine
manufacturing

4
Inappropriate infrastructure, equipment
and materials
Limited financial resources and
partnerships
Weak regulatory systems
Insufficient technical knowledge in
bio-manufacturing
Regional vaccine production status before COVID-19
Challenges
Lack of a coherent strategy for research,
production and regulation

5
Regional vaccine production status after COVID-19
Eight COVID-19 vaccines manufactured
Expressed interest and need to produce
vaccines
Morocco and the United Arab Emirates
became new vaccine-producing countries
Investments made in strengthening the
vaccine regulatory system

6
WHO support
Expert
consultation
CEPI
survey
WHO local
production
assistance
Strengthening
of national
regulatory
authorities
Support given to
mRNA technology
transfer
CEPI = Coalition for Epidemic Preparedness Innovations
mRNA = messenger ribonucleic acid

Regional strategy to strengthen local
vaccine production (1)
7
Goal
Ensure regional vaccine security by
promoting efficient and sustainable
local vaccine production

8
Regional strategy to strengthen local
vaccine production (2)
Key considerations for efficient and sustainable vaccine production
Government
support
Infrastructure
& manufacturing
capacity
Regulatory
systems
Workforce
development
Partnerships
& scientific
technology
transfer
Vaccine
market

9
Regional strategy to strengthen local
vaccine production (3)
Regional
strategy
Establishing
strategic plans
SO1 Facilitating
technology transfer
& partnerships
SO2
Investing in
vaccine-production
workforce
SO3 Strengthening
regulatory
capacities
SO4
SO = strategic objective

10
Regional strategy to strengthen local
vaccine production (4)
Critical
actions to
achieve the
strategic
objectives
• Plan of Action
• Feasibility studies
• Business plan
• Research & Development
• Production of constituents
and commodities
• Develop institutional
development plan
• Technology transfer
• Partnerships
• Manufacturers’ networking
Capacity-building

11
Questions
Local vaccine production:
a priority for the Eastern
Mediterranean Region
What is needed to finalize the regional
strategy and ensure its effective
implementation?
What are your expectations from WHO?

THANK YOU
Langarh@who.int
Dr Houda Langar
Regional Advisor, AMT | UHS

The document summarizes Sinovac Biotech's plans to invest in the pharmaceutical sector in developing countries in Africa. It discusses the environmental prerequisites needed, including political, economic, social/cultural, technical, and legal/regulatory factors. It specifically examines Sinovac's plans to work in South Africa and Kenya, including evaluating the market size and regulatory environment. Sinovac aims to partner with various local organizations through approaches like joint ventures or distributing vaccines to expand access to vaccines in Africa.

Perak biotechnology strategic blueprint 2011 2015

jongos89

The document outlines Perak's strategic blueprint for biotechnology development from 2011-2015. The vision is to establish Perak as a leader in biodiversity-based biotechnology through 6 strategic thrusts: 1) acquiring and developing technologies, 2) leveraging niche areas, 3) developing support facilities, 4) supportive public policies, 5) preparing an educated workforce, and 6) encouraging investment. Key projects include establishing a biotechnology park, advisory center, and the Global Tropical Life Sciences Institute to develop human capital and attract investment in the state's biotechnology sector.

Stage is set for a strong link between1[1]

lankansikh

This document discusses the strong link between microbiology and epidemiology in Sri Lanka's immunization program (NIP). It summarizes key milestones in vaccine introduction and surveillance systems. It also discusses new partners like GAVI that have accelerated vaccine development and introduction plans. While new vaccines like Hib, JE, and pneumococcal may be introduced, sustainability, safety, and cost issues must be considered. Ongoing surveillance and research collaborations between epidemiologists and microbiologists will help inform decision making around introducing additional benefits of vaccines to the Sri Lankan public.

Ebola vaccine market analysis

Dimitrios Gouglas

Country Status Reports on Agricultural Biotechnology - Taiwan

apaari

This document outlines Taiwan's national strategies for promoting agricultural biotechnology. It discusses focusing research on agricultural genomics, new plant and animal breeds, animal and plant health management, and regenerating resources. It also examines opportunities like Taiwan's biodiversity but challenges such as climate change impacts. The future outlook aims to develop next generation genomics, produce competitive new varieties, reinforce health management, and create value-added functional products through applying cyclic regeneration technologies. The long-term goal is to establish sustainable industries to overcome challenges and expand safe recycling agriculture.

Planting the orchard – an ILRI livestock vaccine initiative (ILVAC)

Leveraging Funds for Basic Research in Agricultural Biotechnology: the ICGEB ...

apaari

Global hiv vaccine market future outlook

KuicK Research

"Global HIV Vaccine Market Future Outlook" Report Highlights: Introduction to HIV Vaccines Issues Related to the Development of HIV Vaccines Parameters for Successful Commercialization of HIV Vaccines Global HIV Vaccines Market Opportunity Analysis Global HIV Vaccine Clinical Pipeline by Company & Phase Global HIV Vaccine Clinical Pipeline: 100 Vaccines Majority Vaccine in Preclinical Phase: 42 Vaccines

In this webinar, you will learn: Trends in vaccine manufacturing Innovative solutions in facility design Case studies and proposals for future vaccine factories Considerations while setting up Quality Management Systems (QMSs) How validation helps accelerate regulatory approval Detailed description: How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities? The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.

Ways Forward – Vaccine Manufacturing Tomorrow

Applying and integrating bioscience innovation for socio-economic development

Niche areas

Thota Hyma

The Indian Council of Agricultural Research (ICAR) started the Niche Areas of Excellence program to build excellence in strategic areas of education and research. The program supports agricultural universities in one or two niche areas to develop expertise. Currently 29 niche areas have been established across 29 universities, focusing on technologies like aquaculture, horticulture, soil management, and more. This document provides details on the niche area on avian vaccines and immunology, including its objectives, technical programs from 2012-2016, monitorable targets, grant funding amounts, investigators, and more.

Vaccine security Meeting - Perspective on challenges oie - M.Stone

Global hiv vaccine market future outlook

KuicK Research

AU NEPAD Addis Meeting March 2023-Kassahun.pptx

KassahunTesfaye4

This document discusses policy options for regulating stacked trait biotech crops in Ethiopia. It provides background on Ethiopia's Ministry of Innovation and Technology, science and technology policy, and biotechnology sector. Gene stacking technology combines two or more genes of interest in a single plant to provide multiple traits. Regulatory approaches for gene stacking differ globally, with the US/Canada requiring no additional approval for hybrid stacks of approved events, while the EU requires separate approval. For Ethiopia, gene stacking could help address multiple agricultural stresses at once and overcome challenges like drought, pests and low soil fertility. The recommendations are to consider a less expensive regulatory system and build capacity for evaluating and developing stacked trait crops.

Vaccine research & innovation

jaayboy69

This document provides information about the "Vaccine Research & Innovation 2010" conference taking place on September 2-3, 2010 in London. The conference will explore opportunities in vaccine research and development and feature key speakers from companies such as Novartis Vaccines, Merck, and Intercell. Attendees will gain insights into topics like overcoming challenges in cancer vaccine development, evaluating immune responses to combination vaccines, and implementing strategies for manufacturing conjugate vaccines. The conference is designed to share successful strategies and innovative technologies for developing more effective vaccines.

Insights from a Global Collaboration Accelerating Vaccine Development with an...

Merck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3Nbb5ug Get insights and best practices from a multinational team establishing a platform for vaccine production. See how a long-term collaboration on a bench-scale process used to produce a Virus Like Particle (VLP) vaccine for SARS-CoV-2 was successfully converted to a robust GMP-compatible, scalable process. The COVID-19 pandemic further emphasized the need for collaboration in the development of urgently needed vaccines and therapeutics. In this webinar, we take you behind the scenes of our collaboration with Technovax and Innovative Biotech in which a scalable VLP vaccine platform was optimized for use in a production facility in Nigeria in response to the need for local production of SARS-CoV-2 vaccines. The flexibility and robustness of the platform will enable its rapid deployment to support the West African pandemic readiness program. Initial development of the VLP process began in late 2019 and by March 2020, was already adapted for production of a SARS-CoV-2 vaccine. In this webinar, you will learn: • About building a priceless collaborative network with integrated solutions • Virus-Like Particle Vaccines • Process Development Overview and Challenges • Pre-clinical Results and Next Steps Presented by: Jose M. Galarza, PhD, President and Founder of TechnoVax Naomi Baer, Business development consultant, Emerging Biotech, BioProcess division Youssef Gaabouri, Eng. , Associate Director, Head of Sales Middle East & Africa, BioProcess division

Insights from a Global Collaboration Accelerating Vaccine Development with an...

Vaccine security Meeting - setting the scene - K.Sumption

Regional strategy to improve access to medicines and vaccines in the Eastern ...

LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE

iQHub

The document discusses leveraging private-public partnerships (PPPs) in COVID-19 pandemic response. It provides context on global vaccine trends pre-COVID, then discusses the major impacts of the pandemic on clinical development, trials, and manufacturing. It highlights the roles of developing country vaccine manufacturers and IVI in responding through PPPs. IVI in particular has built partnerships across regions and leveraged over $30 million to develop affordable vaccines for cholera, typhoid and other diseases.

Key achievements and strategic impacts

Update on animal health component 1.1

Inovio Pharmaceuticals, Inc.

1. The document outlines an animal health component that focuses on developing vaccines, diagnostics, and biosecurity protocols for infectious diseases through two interdependent activities: value chain assessments and current projects using generic platforms. 2. Key outputs by 2012-2013 include improved diagnostics and vaccines for diseases like East Coast fever, CBPP, and ASF, as well as thermostabilized PPR vaccines and biosecurity protocols. 3. Overall outcomes include better systems for delivering animal health technologies, increased access to services for smallholders, and improved productivity and economic returns in value chains.

Shrimp industry Bangladesh

Md Arif Hasan

The document outlines plans to rejuvenate the shrimp industry through long term sustainability, modernization, and effective communication. Key plans include implementing disease management and quality control, increasing technical assistance and monitoring, ensuring political stability and proper farming conditions, introducing genetics research, and digitalizing the industry through software and pathogen testing. Long term sustainability focuses on quality larvae production, infrastructure growth, traceability, training farmers, and biotechnology research. Modernization plans center on using biotechnology, digital tools, and developing disease-resistant hybrid shrimp varieties. Effective communication involves raising awareness through online media, workshops, and standardized domestic and overseas advertising.

What does it take to introduce a new vaccine in gavi eligible countries?

JSI

Covid 19 Vaccination SCM Analysis

TejNarayanShaw2

The presentation depicts the supply chain management of the Covid-19 vaccination drive in India. It also focuses on the implementation of Industry 4.0 and digitization of the process to make the vaccination drive a success, Asides, it also briefs about the vaccine candidates in use and prospected to be used in India until 6th June '21. SWOT analysis of the vaccination drive in India is also provided in this presentation.

Crisis Management Protocols

Francois Stepman

The document outlines crisis management protocols for food safety and environmental crises. It discusses the basics of crisis management including legal frameworks, trained personnel, and surveillance systems. It emphasizes the important role of the health system in detecting outbreaks and the prerequisites for effective crisis management such as established reporting procedures and laboratory capacity. Good communication is also highlighted as critical support for crisis management. The document argues that each crisis is a learning experience and situations are always evolving, requiring adapted responses. It discusses how the ACE project aims to monitor emerging hazards and risks and could help update training to improve food safety compliance at the community level. Finally, it notes ways the ACE project and Africa's development goals are mutually beneficial, such as aligning research priorities

Inovio Pharmaceuticals Presentation

Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases. They have demonstrated efficacy of their VGX-3100 immunotherapy in a phase II trial for HPV-related cervical dysplasia. Inovio plans to start a phase III trial for VGX-3100 in 2017 and pursue other HPV-related indications. They are also developing immunotherapies for cancers in combination with checkpoint inhibitors, with a phase I/II trial starting in early 2017. In addition, Inovio is developing vaccines for infectious diseases like HIV, Ebola, Zika, and hepatitis B, with phase I data expected in 2017 that could support further development.

Introduction to the report on implementing Vision 2023.pptx

The 14th WHO General Programme of Work.pptx

The document summarizes the development process and timeline for the 14th WHO General Programme of Work (GPW 14) covering 2025-2028. It outlines the rationale for a new global health strategy given a dramatically changing world. The goal is to promote, provide, and protect health for all. Six strategic objectives are proposed to achieve this: achieve transformative action on climate and health; ensure health is central to policies driving determinants; address inequities in essential health services and interventions; reverse trends in catastrophic health spending; rapidly respond to acute crises and ensure essential services in protracted crises; and ensure all countries are prepared to prevent and mitigate health risks. The next steps outlined are to define WHO's major cross

Similar to Local vaccine production: a priority for the Eastern Mediterranean Region

Ways Forward – Vaccine Manufacturing Tomorrow

Merck Life Sciences

Ways Forward – Vaccine Manufacturing Tomorrow

Applying and integrating bioscience innovation for socio-economic development

Niche areas

Thota Hyma

Vaccine security Meeting - Perspective on challenges oie - M.Stone

Global hiv vaccine market future outlook

KuicK Research

AU NEPAD Addis Meeting March 2023-Kassahun.pptx

KassahunTesfaye4

Vaccine research & innovation

jaayboy69

Insights from a Global Collaboration Accelerating Vaccine Development with an...

Merck Life Sciences

Insights from a Global Collaboration Accelerating Vaccine Development with an...

Vaccine security Meeting - setting the scene - K.Sumption

Regional strategy to improve access to medicines and vaccines in the Eastern ...

LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE

iQHub

Key achievements and strategic impacts

Update on animal health component 1.1

Inovio Pharmaceuticals, Inc.

Shrimp industry Bangladesh

Md Arif Hasan

What does it take to introduce a new vaccine in gavi eligible countries?

JSI

Covid 19 Vaccination SCM Analysis

TejNarayanShaw2

Crisis Management Protocols

Francois Stepman

Inovio Pharmaceuticals Presentation

Similar to Local vaccine production: a priority for the Eastern Mediterranean Region (20)

Ways Forward – Vaccine Manufacturing Tomorrow

Applying and integrating bioscience innovation for socio-economic development

Niche areas

Vaccine security Meeting - Perspective on challenges oie - M.Stone

Global hiv vaccine market future outlook

AU NEPAD Addis Meeting March 2023-Kassahun.pptx

Vaccine research & innovation

Insights from a Global Collaboration Accelerating Vaccine Development with an...

Vaccine security Meeting - setting the scene - K.Sumption

Regional strategy to improve access to medicines and vaccines in the Eastern ...

LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE

Key achievements and strategic impacts

Update on animal health component 1.1

Shrimp industry Bangladesh

What does it take to introduce a new vaccine in gavi eligible countries?

Covid 19 Vaccination SCM Analysis

Crisis Management Protocols

Inovio Pharmaceuticals Presentation

More from WHO Regional Office for the Eastern Mediterranean

Introduction to the report on implementing Vision 2023.pptx

The 14th WHO General Programme of Work.pptx

Transformation update.pptx

The document summarizes updates on WHO's regional transformation efforts. It discusses the creation of an Action for Results Group to develop a regional action plan focused on empowering country offices. This includes ensuring effective ways of working, sufficient resources and capacities, and delegation of authority. Major results include developing cooperation strategies between countries and accelerating working groups. Next steps are continuing implementation to drive impact, scaling capacities, engaging member states, and strengthening WHO's leadership role.

Review of the draft provisional agenda of the 154th Session of the WHO Execut...

The document summarizes the agenda items for the 154th session of the WHO Executive Board to be held from 22 January to 27 February 2024. It will address 26 agenda items under the four pillars of the GPW13: (1) universal health coverage, (2) health emergencies, (3) health and well-being, and (4) effective and efficient WHO support to countries. It also lists additional agenda items proposed by Iraq, Morocco, Qatar, and Somalia. The session will be held in-person in Geneva and will include adoption of the agenda, reports from the Director-General and regional committees, and matters relating to budgets, management, and future World Health Assembly sessions.

Resolutions and decisions of regional interest adopted by the Seventy-sixth W...

World Health Assembly and Executive Board.pptx

The document discusses WHO's proposed approach for its first Investment Round in late 2024. It notes that the Investment Round is a key step in WHO's transformation towards sustainable financing. It provides a timeline of recent events leading up to the Investment Round, including the approval of a new resource mobilization strategy and decisions by the World Health Assembly and Executive Board. It outlines objectives for the Investment Round such as improving WHO's sustainable financing, broadening its donor base, and increasing fundraising efficiency. The document proposes a roadmap and approach for planning the Investment Round that emphasizes co-creation with Member States and bringing together global health partners to rally support around WHO's 14th General Programme of Work and turn the tide on achieving SDG 3 of ensuring

A sustainable, integrated approach to the prevention, control and elimination...

This document proposes a collaborative, integrated approach to preventing, controlling, and eliminating vector-borne diseases in the Eastern Mediterranean region. It notes the increasing burden of these diseases, driven by factors like climate change, conflict, and urbanization. It advocates addressing the three main vector-borne disease groups - caused by Anopheles, Aedes, and other vectors - together rather than separately. This integrated approach would leverage existing programmatic strengths while consolidating resources for more efficient and effective surveillance, control, and response efforts against all vector-borne diseases in the region.

World Health Assembly and Executive Board – Programme and budget matters

Climate change, health and environment a regional framework for action 20232...

The document proposes a new regional framework for action on climate change, health, and the environment from 2023-2029. The previous framework from 2017-2021 had unfinished goals. If adopted, the new framework would help countries implement the WHO COP26 Health Programme and build on other recent regional initiatives. It outlines objectives like building climate-resilient health systems and prioritizing health in climate policies. Targeted changes include integrating health into climate negotiations and developing evidence on the health impacts of climate mitigation and adaptation. The framework provides examples of strategic country actions and requests that member states designate focal points, implement plans of action, and commit resources to strengthen climate resilience in health systems.

Health workforce in the Eastern Mediterranean Region from COVID-19 lessons to...

The document discusses the health workforce challenges in the Eastern Mediterranean region. It notes that 90% of countries faced disruptions to essential health services due to COVID-19, with 66% attributing the disruptions to health workforce issues. The region will face a shortage of over 2 million health workers by 2030. It outlines strategic objectives and calls for accelerated action to enhance and scale up a fit-for-purpose health workforce through mobilizing investments, transforming education, strengthening primary care and emergency response capabilities, and addressing issues like international mobility and retention.

Strengthening public health readiness for mass gatherings in the Eastern Medi...

This document discusses strengthening public health readiness for mass gatherings in the Eastern Mediterranean Region. It begins by defining mass gatherings and the obligations under the International Health Regulations. It then outlines some of the public health threats that can arise from mass gatherings, including infectious diseases, non-communicable diseases, injuries, and psychological impacts. However, it also notes that mass gatherings can create opportunities to enhance health systems and increase disease prevention awareness. The document discusses examples of WHO's support for mass gatherings in the region. It proposes a regional framework to guide countries in establishing arrangements and capacities to safely host mass gatherings. The framework focuses on risk assessment, health system strengthening, multisectoral coordination, partnerships, planning, and

Addressing noncommunicable diseases in emergencies: a regional framework for ...

This document proposes a regional framework for addressing noncommunicable diseases (NCDs) in emergencies. It notes that almost half of countries in the region face emergencies like conflicts, natural disasters, or financial crises. People with NCDs are more vulnerable during emergencies due to disrupted health services, competing priorities, and insecurity. The framework establishes guidelines for integrating NCD care into emergency response, including continuity of services through emergency kits, and adapting delivery models across preparedness, response, and recovery phases. It calls on member states to invest in NCDs and strengthen data collection, and for WHO to support NCD integration and partnerships. The overall aim is to balance priorities and ensure NCD care

Ending polio by the end of 2023.pptx

This document discusses efforts to end polio transmission by the end of 2023. It summarizes the status of wild poliovirus and vaccine-derived poliovirus outbreaks in various countries. While the goal of stopping wild poliovirus transmission in Afghanistan and Pakistan by mid-2024 is now considered "off track", interruption of transmission is still possible within the next six months. However, stopping global transmission of circulating vaccine-derived poliovirus type 2 will likely be missed. The document requests that regional and national commitments be sustained to stop endemic polio and help chart a pathway to protect children in Yemen.

Emergencies and the IHR (2005) in the Eastern Mediterranean Region.pptx

This document discusses emergency response challenges and opportunities in the Eastern Mediterranean region. It notes that the number of people in need of humanitarian assistance has increased 117-110% since 2015 and outlines the top countries burdened by fragility, conflict, and refugee crises. While COVID-19 response increased some capacities, preparedness remains a challenge. The document highlights some response successes but also areas needing improvement like operational readiness and fragmentation. It concludes by emphasizing opportunities to sustain COVID gains through resilience-building, and priorities around preparedness, high-threat pathogens, protracted crises, and supply chain management.

Embrace the change National programmes for the development and adaptation of ...

This document discusses the importance of national clinical practice guideline programs. It notes that while evidence-based medicine has been emphasized since the 1990s, 70% of countries in the WHO Eastern Mediterranean Region still lack formal guideline development and implementation programs. The document outlines the benefits of national programs, including increasing quality of care, efficiency, and health outcomes. It also analyzes challenges faced by many countries, such as limited resources and capacity. The document describes WHO initiatives to support countries in establishing their own programs, using Egypt as an example. It emphasizes the need for high-level commitment, stakeholder engagement, and expanded national capacities to effectively develop and implement evidence-informed clinical guidelines.

Minimise morbidity and mortality due to trauma in humanitarian emergencies.pptx

This document discusses the public health burden of trauma in humanitarian emergencies in the Eastern Mediterranean Region (EMR). It notes that many countries in the region experience conflicts, violence, natural disasters and fragile situations that result in trauma. Trauma outcomes are often worse in low-income countries due to limited pre-hospital and hospital trauma care services. The document proposes a regional initiative to minimize trauma morbidity and mortality through coordinated leadership, workforce training programs, and support to priority fragile countries to strengthen pre-hospital services, train hospital staff in mass casualty management, and develop accredited trauma training courses. It provides some examples of initial progress made through this initiative.

Designing and implementing primary health care-oriented models of care in the...

Minimizing morbidity and mortality due to trauma in humanitarian emergencies....

This document proposes a regional approach to minimizing trauma-related morbidity and mortality in humanitarian emergencies. It notes the high public health burden of trauma in conflict-affected countries in the region like Afghanistan, Iraq, Syria, and Yemen. Prehospital care is limited, over 60% of trauma deaths occur before reaching the hospital, and fatality rates are triple those in high-income countries. The proposal calls for member states to support a Regional Trauma Initiative that coordinates partners, invests in prehospital care and the health care workforce through dedicated training programs, and utilizes regional expertise to build emergency care systems and support fragile contexts.

Nomination of a Member State to the Joint Coordinating Board of the Special P...

WHA resolutions and decisions of regional interest.pptx

More from WHO Regional Office for the Eastern Mediterranean (20)

Introduction to the report on implementing Vision 2023.pptx

The 14th WHO General Programme of Work.pptx

Transformation update.pptx

Review of the draft provisional agenda of the 154th Session of the WHO Execut...

Resolutions and decisions of regional interest adopted by the Seventy-sixth W...

World Health Assembly and Executive Board.pptx

A sustainable, integrated approach to the prevention, control and elimination...

World Health Assembly and Executive Board – Programme and budget matters

Climate change, health and environment a regional framework for action 20232...

Health workforce in the Eastern Mediterranean Region from COVID-19 lessons to...

Strengthening public health readiness for mass gatherings in the Eastern Medi...

Addressing noncommunicable diseases in emergencies: a regional framework for ...

Ending polio by the end of 2023.pptx

Emergencies and the IHR (2005) in the Eastern Mediterranean Region.pptx

Embrace the change National programmes for the development and adaptation of ...

Minimise morbidity and mortality due to trauma in humanitarian emergencies.pptx

Designing and implementing primary health care-oriented models of care in the...

Minimizing morbidity and mortality due to trauma in humanitarian emergencies....

Nomination of a Member State to the Joint Coordinating Board of the Special P...

WHA resolutions and decisions of regional interest.pptx

Recently uploaded

G7 Apulia Leaders Communique, June 2024 (1).pdf

一比一原版英国阿伯丁大学毕业证(AU毕业证书)学历如何办理

afsebu

退学办理文凭【微信号:176555708】【(AU毕业证书)】【微信号:176555708】《成绩单、外壳、offer、真实留信官方学历认证（永久存档/真实可查）》采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。【我们承诺采用的是学校原版纸张（纸质、底色、纹路）我们拥有全套进口原装设备，特殊工艺都是采用不同机器制作，仿真度基本可以达到100%，所有工艺效果都可提前给客户展示，不满意可以根据客户要求进行调整，直到满意为止！】【业务选择办理准则】一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信号:176555708】文凭即可二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信号:176555708】即可三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。留信网认证的作用: 1:该专业认证可证明留学生真实身份 2:同时对留学生所学专业登记给予评定 3:国家专业人才认证中心颁发入库证书 4:这个认证书并且可以归档倒地方 5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息 6:个人职称评审加20分 7:个人信誉贷款加10分 8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才留信网服务项目： 1、留学生专业人才库服务（留信分析） 2、国（境）学习人员提供就业推荐信服务 3、留学人员区块链存储服务【关于价格问题（保证一手价格）】我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子我给客户的都是第一手的代理价格，因为我想坦诚对待大家不想跟大家在价格方面浪费时间对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。选择实体注册公司办理，更放心，更安全！我们的承诺：客户在留信官方认证查询网站查询到认证通过结果后付款，不成功不收费！

Call Girls Ahmedabad 🌹 7339748667 🌹 With No Advance Payment

prijesh mathew

GUIA_LEGAL_CHAPTER_6_IMMIGRATION_REGIME.pdf

ProexportColombia1

UN SDSN Sustainable Development Report 2024

Congressional Budget Office

Spending in the 340B Drug Pricing Program, 2010 to 2021

The cost of poor health: What does rising health-related benefit spending mea...

ResolutionFoundation

G7 Apulia Leaders Communique, 14th June 2024

Call Girls in Kolkata (West Bengal) call me [🔝9352988975🔝] Escort In Kolkata ...

deepakrana121234

Russian Call Girls Visakhapatnam 8800000000 Low Rate HIgh Profile Visakhapatn...

khannsohil539

一比一原版加拿大麦科文大学毕业证如何办理

qypomky

原版一模一样【微信：741003700 】【加拿大麦科文大学毕业证成绩单】【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。本公司拥有海外各大学样板无数，能完美还原。 1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700 【主营项目】一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！二.真实使馆公证(即留学回国人员证明,不成功不收费) 三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度) 如果您处于以下几种情况： ◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】 ◇面对父母的压力，希望尽快拿到； ◇不清楚认证流程以及材料该如何准备； ◇回国时间很长，忘记办理； ◇回国马上就要找工作，办给用人单位看； ◇企事业单位必须要求办理的 ◇需要报考公务员、购买免税车、落转户口 ◇申请留学生创业基金留信网认证的作用: 1:该专业认证可证明留学生真实身份 2:同时对留学生所学专业登记给予评定 3:国家专业人才认证中心颁发入库证书 4:这个认证书并且可以归档倒地方 5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息 6:个人职称评审加20分 7:个人信誉贷款加10分 8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才办理加拿大麦科文大学毕业证【微信：741003700 】外观非常简单，由纸质材料制成，上面印有校徽、校名、毕业生姓名、专业等信息。办理加拿大麦科文大学毕业证【微信：741003700 】格式相对统一，各专业都有相应的模板。通常包括以下部分：校徽：象征着学校的荣誉和传承。校名:学校英文全称授予学位：本部分将注明获得的具体学位名称。毕业生姓名：这是最重要的信息之一，标志着该证书是由特定人员获得的。颁发日期：这是毕业正式生效的时间，也代表着毕业生学业的结束。其他信息：根据不同的专业和学位，可能会有一些特定的信息或章节。办理加拿大麦科文大学毕业证【微信：741003700 】价值很高，需要妥善保管。一般来说，应放置在安全、干燥、防潮的地方，避免长时间暴露在阳光下。如需使用，最好使用复印件而不是原件，以免丢失。综上所述，办理加拿大麦科文大学毕业证【微信：741003700 】是证明身份和学历的高价值文件。外观简单庄重，格式统一，包括重要的个人信息和发布日期。对持有人来说，妥善保管是非常重要的。

Jabatan Fungsional: Konsep, Peran & Prospeknya

Tri Widodo W. UTOMO

EI Statistical Review of World Energy 2024